- Home
- NMRA vs MTLS Comparison
NMRA vs MTLS Comparison
Compare NMRA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- MTLS
- Stock Information
- Founded
- NMRA 2019
- MTLS 1990
- Country
- NMRA United States
- MTLS Belgium
- Employees
- NMRA N/A
- MTLS N/A
- Industry
- NMRA
- MTLS Computer Software: Prepackaged Software
- Sector
- NMRA
- MTLS Technology
- Exchange
- NMRA Nasdaq
- MTLS Nasdaq
- Market Cap
- NMRA 287.6M
- MTLS 297.1M
- IPO Year
- NMRA 2023
- MTLS 2014
- Fundamental
- Price
- NMRA $1.16
- MTLS $5.32
- Analyst Decision
- NMRA Buy
- MTLS Buy
- Analyst Count
- NMRA 8
- MTLS 1
- Target Price
- NMRA $10.14
- MTLS $9.50
- AVG Volume (30 Days)
- NMRA 1.3M
- MTLS 497.1K
- Earning Date
- NMRA 03-03-2025
- MTLS 04-24-2025
- Dividend Yield
- NMRA N/A
- MTLS N/A
- EPS Growth
- NMRA N/A
- MTLS 106.79
- EPS
- NMRA N/A
- MTLS 0.24
- Revenue
- NMRA N/A
- MTLS $276,182,835.00
- Revenue This Year
- NMRA N/A
- MTLS $6.55
- Revenue Next Year
- NMRA N/A
- MTLS $9.21
- P/E Ratio
- NMRA N/A
- MTLS $22.46
- Revenue Growth
- NMRA N/A
- MTLS 4.15
- 52 Week Low
- NMRA $1.13
- MTLS $4.70
- 52 Week High
- NMRA $17.19
- MTLS $9.69
- Technical
- Relative Strength Index (RSI)
- NMRA 28.13
- MTLS 37.85
- Support Level
- NMRA $1.13
- MTLS $5.15
- Resistance Level
- NMRA $1.48
- MTLS $5.46
- Average True Range (ATR)
- NMRA 0.13
- MTLS 0.18
- MACD
- NMRA 0.06
- MTLS 0.13
- Stochastic Oscillator
- NMRA 17.03
- MTLS 85.59
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.